Cat No.
CEI-0040
Description
Cediranib (AZD2171) can inhibit VEGFR2, FLT-1 and FLT-4 with IC50 of 0.5 nM, 5 nM and 3 nM.
Alias
Recentin
Synonyms
Recentin
CAS No.
288383-20-0
Targets
VEGFR2, FLT-1, FLT-4
Chemical Name
4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline
M.Wt
450.51
Purity
>99%
Solubility
DMSO 90 mg/mL Water
Storage
2 years at -20centigrade Powder
In vitro
AZD2171 is a novel indole-ether quinazoline inhibitor. AZD2171, as an ATP-competitive inhibitor, can potently inhibit KDR tyrosine kinase with IC50 less than 1 nM in vitro. AZD2171 are consistent with potent inhibition of VEGF signaling, angiogenesis, neovascular survival, and tumor growth.In human umbilical vein endothelial cells, AZD2171 inhibited VEGF-stimulated proliferation and KDR phosphorylation with IC50 values of 0.4 nM and 0.5 nM, respectively. In a fibroblast/endothelial cell coculture model of vessel sprouting, AZD2171 also reduced vessel area, length, and branching at subnanomolar concentrations.
